T1D RELAY Study - Ages 8-17
STUDY BASICS
Are you the parent of a child 8 - 17 that is newly diagnosed with type 1 diabetes? Your child may be eligible for a research study to see if the use of two drugs-rituximab-pvvr followed by abatacept will help to preserve remaining insulin in people with newly diagnosed diabetes. Participation involves 21 visits over 4 years. Compensation is provided.
STUDY PURPOSE
The purpose is to study the use of rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extend insulin production in people newly diagnosed with type 1 diabetes (T1D). Each participant will receive the rituximab-pvvr but then randomized to either abatacept or placebo.
COULD THIS STUDY BE RIGHT FOR YOUR CHILD?
- Age 8 to 17
- Child is newly diagnosed with type 1 diabetes (less than 3 months ago)
WHAT PARTICIPANTS CAN EXPECT
All participants will receive investigational treatment of either rituximab-pvvr followed by abatacept or rituximab-pvvr followed by placebo.
Schedule of Visits
- Screening Visit
- Treatment Phase – 15 visits over about 24 months
- Follow-Up Phase – 5 visits over about 24 months
IRB: STUDY21040103B
- Rituximab-pvvr followed by Abatacept verses Rituximab-pvvr Alone in New Onset Type 1 DiabetesMEET THE RESEARCHER
![](/imagelibrary/getimagegrayscale?FileName=ilibman.png)
Ingrid Libman DeGordon
Ingrid Libman DeGordon, MD, PhD, is an Associate Professor in the Division of Pediatric Endocrinology at the University of Pittsburgh School of Medicine and Director of the UPMC Children’s Hospital of Pittsburgh Diabetes Program. A graduate of the University of Pittsburgh Graduate School of Public Health, Dr. Libman’s research interests include prediction, prevention and management of diabetes in youth, the impact of obesity in type 1 diabetes and the concept of “double” diabetes in childhood.